A detailed history of Vanguard Group Inc transactions in Hookipa Pharma Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,120,473 shares of HOOK stock, worth $8.04 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,120,473
Previous 2,118,416 0.1%
Holding current value
$8.04 Million
Previous $1.5 Million 16.82%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$0.59 - $1.04 $1,213 - $2,139
2,057 Added 0.1%
2,120,473 $1.25 Million
Q1 2024

May 10, 2024

BUY
$0.61 - $0.83 $2,204 - $2,999
3,614 Added 0.17%
2,118,416 $1.5 Million
Q4 2023

Feb 14, 2024

BUY
$0.42 - $0.86 $124,870 - $255,686
297,310 Added 16.36%
2,114,802 $1.71 Million
Q3 2023

Nov 14, 2023

SELL
$0.58 - $0.91 $2,368 - $3,715
-4,083 Reduced 0.22%
1,817,492 $1.13 Million
Q2 2023

Aug 14, 2023

BUY
$0.71 - $1.97 $49,344 - $136,913
69,499 Added 3.97%
1,821,575 $1.6 Million
Q4 2022

Feb 10, 2023

SELL
$0.73 - $14.6 $8,427 - $168,557
-11,545 Reduced 0.65%
1,752,076 $1.42 Million
Q3 2022

Nov 14, 2022

BUY
$1.27 - $15.0 $142,100 - $1.68 Million
111,890 Added 6.77%
1,763,621 $2.36 Million
Q2 2022

Aug 12, 2022

BUY
$1.33 - $2.31 $708,703 - $1.23 Million
532,860 Added 47.62%
1,651,731 $2.69 Million
Q1 2022

May 13, 2022

BUY
$1.26 - $2.52 $259,949 - $519,898
206,309 Added 22.61%
1,118,871 $2.55 Million
Q4 2021

Feb 14, 2022

BUY
$2.33 - $5.94 $2,010 - $5,126
863 Added 0.09%
912,562 $2.13 Million
Q3 2021

Nov 12, 2021

BUY
$5.89 - $9.35 $62,139 - $98,642
10,550 Added 1.17%
911,699 $5.37 Million
Q2 2021

Aug 13, 2021

BUY
$9.16 - $19.51 $8.25 Million - $17.6 Million
901,149 New
901,149 $8.26 Million

Others Institutions Holding HOOK

About HOOKIPA Pharma Inc.


  • Ticker HOOK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,654,500
  • Market Cap $196M
  • Description
  • HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transpl...
More about HOOK
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.